Qualitative assessment of DRB18 and vehicle-treated tumor sections via immunofluorescence showed DRB18 decreased expression of GLUT1-4 (Fig. 5f) and reduced proliferative capacity within the xenografted tumor, indicated by fewer Ki67-positive cells, compared with vehicle-treated samples. This evidence concerns the gene SLC2A14 and neoplasm.